COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Reviva Pharmaceuticals Holdings, Inc. • September 7th, 2022 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 8, 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on September 8, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 7th, 2022 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”), dated as of September 6, 2022, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
5,500,000 Units Tenzing Acquisition Corp. UNDERWRITING AGREEMENTUnderwriting Agreement • August 24th, 2018 • Tenzing Acquisition Corp. • Blank checks • New York
The undersigned, Tenzing Acquisition Corp., a British Virgin Islands company (“Company”), hereby confirms its agreement with Maxim Group LLC (hereinafter referred to as “you”, “ Maxim”, or as the “Representative”) and with the other underwriters named on Schedule A hereto for which you are acting as representative (the Representative and the other Underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 24th, 2018 • Tenzing Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of August 20, 2018, by and among Tenzing Acquisition Corp., a British Virgin Islands company (the “Company”), Tenzing LLC (the “Sponsor Investor”), Maxim Group LLC (the “Maxim Investor” and, together with the Sponsor Investor, the “Investors”, and each individually, an “Investor”) and any other holder of Registrable Securities (as defined below) which becomes a party to this Agreement pursuant to Section 6.2.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Reviva Pharmaceuticals Holdings, Inc. • May 25th, 2021 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Reviva Pharmaceuticals Holdings, Inc. • August 16th, 2021 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [___________] by and between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 17th, 2023 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 15, 2023, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT AGREEMENTWarrant Agreement • August 24th, 2018 • Tenzing Acquisition Corp. • Blank checks • New York
This Warrant Agreement (this “Agreement”) made as of August 20, 2018 between Tenzing Acquisition Corp., a British Virgin Islands company, with offices at 250 West 55th Street, New York, NY 10019 (“Company”), and Continental Stock Transfer& Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warrant Agent”).
REVIVA PHARMACEUTICALS HOLDINGS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant AgentWarrant Agency Agreement • August 16th, 2021 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of June 1, 2021 (“Agreement”), between Reviva Pharmaceuticals Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Continental Stock Transfer & Trust Company (the “Warrant Agent”).
COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Common Stock Purchase • August 16th, 2021 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 1, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject t
September 6, 2022 Reviva Pharmaceuticals Holdings, Inc. 19925 Stevens Creek Boulevard, Suite 100 Cupertino, CA 95014 Attn: Dr. Laxminarayan BhatReviva Pharmaceuticals Holdings, Inc. • September 7th, 2022 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) shares of common stock of the Company, par value $0.0001 per share (the “Shares”), (ii) warrants to purchase Shares (the “Common Warrants”) and (iii) pre-funded warrants to purchase Shares (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities”, which shall include, for the avoidance of doubt, any shares placed with Vedanta Associates, LP or any of its affiliates. The terms of the Placement shall be mutually agreed upon by the Company and the purch
AT THE MARKET OFFERING AGREEMENTMarket Offering Agreement • January 26th, 2022 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Reviva Pharmaceuticals Holdings, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
UNIT SUBSCRIPTION AGREEMENTUnit Subscription Agreement • August 16th, 2018 • Tenzing Acquisition Corp. • Blank checks • Virgin Islands
This UNIT SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this 16th day of August, 2018, by and between Tenzing Acquisition Corp., a company incorporated in the British Virgin Islands with number 1973495 (the “Company”), having its principal place of business at 250 West 55th Street, New York, New York 10019, and Maxim Group LLC (the “Purchaser”).
SHARES OF COMMON STOCK ___________ PRE- FUNDED WARRANTS TO PURCHASE ___________ SHARES OF COMMON STOCK, AND ___________ WARRANTS TO PURCHASE ___________ SHARES OF COMMON STOCK OF REVIVA PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 25th, 2021 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
The undersigned, Reviva Pharmaceuticals Holdings, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries of Reviva Pharmaceuticals Holdings, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 14, 2020, by and between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (formerly Tenzing Acquisition Corp., a company incorporated in the British Virgin Islands (the “Predecessor”)) (together with the Predecessor and its successors, the “Company”), and [__________] (“Holder”).
AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER by and amongAgreement and Plan of Merger • July 24th, 2020 • Tenzing Acquisition Corp. • Blank checks • New York
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of July 20, 2020 by and among (i) Tenzing Acquisition Corp, a company incorporated in the British Virgin Islands (together with its successors, including after the Conversion (as defined below), the “Purchaser”), (ii) Tenzing Merger Subsidiary Inc., a Delaware corporation and a wholly-owned subsidiary of the Purchaser (“Merger Sub”), (iii) Tenzing LLC, a Delaware limited liability company, in the capacity as the representative from and after the Effective Time (as defined below) for the stockholders of the Purchaser (other than the Company Security Holders (as defined below) as of immediately prior to the Effective Time and their successors and assignees) in accordance with the terms and conditions of this Agreement (the “Purchaser Representative”), (iv) Laxminarayan Bhat in the capacity as the representative from and after the Effective Time for the Company Stockholders (as defined below) as of immediatel
INDEMNITY AGREEMENTIndemnity Agreement • August 6th, 2018 • Tenzing Acquisition Corp. • Blank checks • New York
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of August __, 2018, by and between TENZING ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and _____________ (“Indemnitee”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • August 24th, 2018 • Tenzing Acquisition Corp. • Blank checks • New York
This Agreement is made as of August 20, 2018 by and between Tenzing Acquisition Corporation (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”).
NON-COMPETITION AND NON-SOLICITATION AGREEMENTNon-Competition and Non-Solicitation Agreement • July 24th, 2020 • Tenzing Acquisition Corp. • Blank checks • Delaware
THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (this “Agreement”) is being executed and delivered as of July 20, 2020, by Laxminarayan Bhat, Ph.D (the “Subject Party”) in favor of and for the benefit of Tenzing Acquisition Corp., a British Virgin Islands corporation (together with its successors, including after the Conversion (as defined below), the “Purchaser”), Reviva Pharmaceuticals, Inc., a Delaware company (the “Company”), and each of the Purchaser’s and/or the Company’s respective present and future Affiliates, successors and direct and indirect Subsidiaries (collectively with the Purchaser and the Company, the “Covered Parties”). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement.
Tenzing Acquisition Corp. New York, New York 10019Tenzing Acquisition Corp. • July 20th, 2018 • Blank checks • Virgin Islands
We are pleased to accept the offer you (the “Subscriber”) have made to purchase an aggregate of 1,437,500 ordinary shares (the “Shares”) of no par value per share (the “Ordinary Shares”), up to 187,500 of which Shares are subject to complete or partial forfeiture (the “forfeiture”) by you if the underwriters of the initial public offering (“IPO”) of Tenzing Acquisition Corp., a British Virgin Islands company (the “Company”) do not fully exercise their over-allotment option (the “Over-allotment Option”). The terms on which the Company is willing to sell the Shares to the Subscriber, and the Company and the Subscriber’s agreements regarding such Shares, are as follows:
NONQUALIFIED STOCK OPTION GRANT AGREEMENT REVIVA PHARMACEUTICALS HOLDINGS, INC.Nonqualified Stock Option Grant Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
INCENTIVE STOCK OPTION GRANT AGREEMENT REVIVA PHARMACEUTICALS HOLDINGS, INC.Incentive Stock Option Grant Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
AMENDED AND RESTATED UNIT SUBSCRIPTION AGREEMENTAmended and Restated Unit Subscription Agreement • August 16th, 2018 • Tenzing Acquisition Corp. • Blank checks • Virgin Islands
This AMENDED AND RESTATED UNIT SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this [ ] day of August, 2018, by and between Tenzing Acquisition Corp., a company incorporated in the British Virgin Islands with number 1973495 (the “Company”), having its principal place of business at 250 West 55th Street, New York, New York 10019, and Tenzing LLC (the “Purchaser”).
Employment AgreementEmployment Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is made and entered into as of December 14, 2020, by and between Laxminarayan Bhat, Ph.D. (the “Executive”) and Reviva Pharmaceuticals Holdings, Inc. (the “Company”).
COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Common Stock Purchase • November 17th, 2023 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November ___, 20281 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
VOTING AGREEMENTVoting Agreement • July 24th, 2020 • Tenzing Acquisition Corp. • Blank checks • New York
This Voting Agreement (this “Agreement”) is made as of July 20, 2020 by and among (i) Tenzing Acquisition Corp., a British Virgin Islands corporation (together with its successors, including the Successor after the Conversion (as such terms are defined in the Merger Agreement, defined below), the “Purchaser”), (ii) Reviva Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (iii) the undersigned stockholder (“Holder”) of the Company. Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement.
PREFUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Prefunded Common Stock • November 17th, 2023 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
NOTE PURCHASE AGREEMENTNote Purchase Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • California
This Note Purchase Agreement (this “Agreement”) is made and entered into as of August 17, 2020, by and among Reviva Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the parties identified on the signature pages hereto (each individually an “Investor” and collectively the “Investors”), and shall become effective upon the consummation of the SPAC Merger (as defined herein).
LOCK-UP AGREEMENTLock-Up Agreement • July 24th, 2020 • Tenzing Acquisition Corp. • Blank checks • New York
THIS LOCK-UP AGREEMENT (this “Agreement”) is made and entered into as of [__], 2020 by and among (i) Tenzing Acquisition Corp. a British Virgin Islands corporation, which will be known after the consummation of the transactions contemplated by the Merger Agreement (as defined below) as “Reviva Pharmaceuticals Holdings, Inc.” (including any successor entity thereto, including the Successor after the Conversion (as such terms are defined in the Merger Agreement), the “Purchaser”), (ii) Tenzing LLC, in the capacity under the Merger Agreement as the Purchaser Representative (including any successor Purchaser Representative appointed in accordance therewith, the “Purchaser Representative”), and (iii) the undersigned (“Holder”). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement.
SHARES OF COMMON STOCK REVIVA PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 10th, 2021 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
The undersigned, Reviva Pharmaceuticals Holdings, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries of Reviva Pharmaceuticals Holdings, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
NON-REDEMPTION AGREEMENTNon-Redemption Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
This NON-REDEMPTION AGREEMENT (this “Agreement”) is entered into as of December 8, 2020, by and among (i) Tenzing Acquisition Corp., a company incorporated in the British Virgin Islands (together with its successors, including after the Conversion (as defined below), “Tenzing”), (ii) Tenzing LLC, a Delaware limited liability company (the “Sponsor”), and (iii) the undersigned shareholder (“Shareholder”). Tenzing, the Sponsor and Shareholder are sometimes referred to herein as a “Party” and collectively as the “Parties”.
Tenzing Acquisition Corp. New York, NY 10019 Rahul Nayar, Chief Executive OfficerTenzing Acquisition Corp. • August 6th, 2018 • Blank checks • New York
This letter is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Tenzing Acquisition Corp., a British Virgin Islands Company (the “Company”), and Maxim Group, LLC. as Representative (the “Representative”) of the several Underwriters named in Schedule A thereto (the “Underwriters”), relating to an underwritten initial public offering (the “IPO”) of the Company’s units (the “Units”), each comprised of one ordinary share, no par value, of the Company (the “Ordinary Shares”), and one warrant (the “Warrant”) to purchase one Ordinary Share. Certain capitalized terms used herein are defined in paragraph 17 hereof.
Tenzing Acquisition CorpBackstop Agreement • October 27th, 2020 • Tenzing Acquisition Corp. • Pharmaceutical preparations
Reference is hereby made to that certain Backstop Agreement, dated as of October ___, 2020 (the “Backstop Agreement”), by and among Tenzing Acquisition Corp., a company incorporated in the British Virgin Islands (together with its successors, the “Company”), Reviva Pharmaceuticals, Inc., a Delaware corporation (together with its successors, “Reviva”), and [insert Investor Name] (“Investor”). Any capitalized term used but not defined in this waiver letter (this “Waiver”) will have the meaning ascribed to such term in the Backstop Agreement.
ESCROW AGREEMENTEscrow Agreement • December 18th, 2020 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
This ESCROW AGREEMENT (this “Agreement”) is made and entered into as of December 14, 2020, by and among: (i) Tenzing Acquisition Corp., a British Virgin Islands corporation, which will be known after the consummation of the transactions contemplated by the Merger Agreement (as defined below) as “Reviva Pharmaceuticals Holdings, Inc.” (including any successor entity thereto, including the Successor after the Conversion (as such terms are defined in the Merger Agreement), the “Purchaser”), (ii) Tenzing LLC, in its capacity under the Merger Agreement as the Purchaser Representative (including any successor Purchaser Representative appointed in accordance therewith, the “Purchaser Representative”), (iii) Laxminarayan Bhat, in his capacity as the Seller Representative under the Merger Agreement (including any successor Seller Representative appointed in accordance therewith, the “Seller Representative”); and (iv) Continental Stock Transfer & Trust Company, as escrow agent (the “Escrow Agent
